These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2030884)

  • 41. The meaning of the "me-too" drug decision.
    Archambault GF
    Hosp Formul; 1975 Oct; 10(10):510. PubMed ID: 10316671
    [No Abstract]   [Full Text] [Related]  

  • 42. FDA's treatment investigational new drug rule: one year later.
    Appler WD
    J Clin Psychopharmacol; 1988 Aug; 8(4):286-7. PubMed ID: 3209720
    [No Abstract]   [Full Text] [Related]  

  • 43. An overview of FDA medical device regulation as it relates to deep brain stimulation devices.
    Peña C; Bowsher K; Costello A; De Luca R; Doll S; Li K; Schroeder M; Stevens T
    IEEE Trans Neural Syst Rehabil Eng; 2007 Sep; 15(3):421-4. PubMed ID: 17894274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety-related drug labeling changes approved by FDA.
    White GG
    J Toxicol Clin Toxicol; 1998; 36(3):265-7. PubMed ID: 9678979
    [No Abstract]   [Full Text] [Related]  

  • 45. Conforming regulations regarding removal of section 507 of the Federal Food, Drug, and Cosmetic Act; confirmation of effective date. Food and Drug Administration, HHS. Direct final rule; confirmation of effective date.
    Fed Regist; 1999 May; 64(94):26657. PubMed ID: 10558515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A taste of new medicine.
    Nat Med; 2006 May; 12(5):481. PubMed ID: 16675969
    [No Abstract]   [Full Text] [Related]  

  • 47. New director at FDA's CDRH.
    FDA Consum; 2004; 38(5):6. PubMed ID: 15595136
    [No Abstract]   [Full Text] [Related]  

  • 48. Talking about...authority.
    Bruttomesso G; Miglino N
    J Thromb Haemost; 2006 Aug; 4(8):1849-50. PubMed ID: 16879236
    [No Abstract]   [Full Text] [Related]  

  • 49. Patents and the US FDA's definition of 'cocrystal': an ordinary and customary meaning?
    Lindeman JA
    Pharm Pat Anal; 2012 Nov; 1(5):513-5. PubMed ID: 24236917
    [No Abstract]   [Full Text] [Related]  

  • 50. FDA's new bureau of veterinary medicine.
    Freeman A
    J Am Vet Med Assoc; 1966 Apr; 148(7):812-3. PubMed ID: 5959969
    [No Abstract]   [Full Text] [Related]  

  • 51. Whatever happened to user fees and the FDA's promise to expedite new drug approvals?
    Gatty B
    Hosp Formul; 1993 Jul; 28(7):656, 655. PubMed ID: 10127048
    [No Abstract]   [Full Text] [Related]  

  • 52. Curbing counterfeit drugs.
    FDA Consum; 2006; 40(5):11. PubMed ID: 17326307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of FDA's new drug rule? Not much.
    Holthaus D
    Hospitals; 1987 Aug; 61(15):106. PubMed ID: 3596532
    [No Abstract]   [Full Text] [Related]  

  • 54. New approaches to FDA's educational program.
    Cunningham ME
    J Am Coll Health Assoc; 1968 Feb; 16(3):260-5. PubMed ID: 5639438
    [No Abstract]   [Full Text] [Related]  

  • 55. New director appointed for FDA's DAVDP unit.
    AIDS Alert; 2002 Feb; 17(2):28. PubMed ID: 11862751
    [No Abstract]   [Full Text] [Related]  

  • 56. FDA's claims over stem cells upheld.
    Cyranoski D
    Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
    [No Abstract]   [Full Text] [Related]  

  • 57. FDA: friend or foe?
    Lewis TS
    Med Device Technol; 1996 Nov; 7(9):24-30. PubMed ID: 10163675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FDA's role in making exclusivity determinations.
    Dickinson EH
    Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573
    [No Abstract]   [Full Text] [Related]  

  • 59. Informed consent: the FDA's perspective.
    Bagley G
    Food Drug Law J; 1993; 48(2):181-6. PubMed ID: 11653141
    [No Abstract]   [Full Text] [Related]  

  • 60. The drug-potency question.
    Walker JM
    US Navy Med; 1974 Aug; 64(2):26-30. PubMed ID: 4534296
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.